関連する実験動画
Updated: Feb 15, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.9K
潰瘍性大腸炎患者のミリキジューマブ治療中の皮膚性自己免疫性水泡性疾患:新たな潜在的なトリガー?
Lucia Centanni1,2, Fabrizio Fanizzi1,2, Ferdinando D'amico1
1Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, Milan, Italy.
Journal of Crohn's & colitis
|February 14, 2026
まとめ
ミリキジウマブのようなインタールイウキン-23 (IL-23) 阻害剤は,潰瘍性大腸炎 (UC) 患者において,自己免疫性水泡性疾患 (AIBD) をめったに誘発することがありません. 迅速な認識と管理は,感受性の高い個人にとって極めて重要です.
科学分野:
- 皮膚科 皮膚科について
- 胃腸内科 胃腸内科
- 免疫学 免疫学とは
背景:
- 自己免疫性水泡性疾患 (AIBD) は,生物学的薬を含む様々な治療法の悪影響として知られています.
- 潰瘍性大腸炎 (UC) 患者におけるIL-23阻害剤とAIBDとの関連に関するデータは限られている.
研究 の 目的:
- UCの患者でミリキジューマブ治療後にAIBDが発症した症例を報告する.
- AIBDを誘発するIL-23阻害剤の可能性を強調する.
主な方法:
- 59歳の男性UC患者の症例報告です.
- ミリキジューマブ注入後の皮のの皮膚の塊の臨床観察.
- 組織病理学的検査と直接免疫光検査.
- ミリキジューマブ離脱とコルチコステロイド治療に対する応答の評価.
主要な成果:
- 患者は,ミリキジューマブ注入後数日以内にAIBDの症状を発症しました.
- 組織病理学と免疫光学でAIBDが確認されました.
- 病変は,ミリキジューマブを中止し,コルチコステロイドを投与すると改善し,関連性を示唆しています.
結論:
- ミリキジューマブは,UCに敏感な患者のAIBDを誘発する可能性がある.
- 臨床医は,このまれな合併症に対して警戒すべきである.
- 適切なタイミングでの認識と管理は不可欠です.
関連する概念動画
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.2K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.2K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
541
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
541
01:28Peptic Ulcer Disease II: Pathophysiology
2.2K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.2K
01:30Peptic Ulcer Disease I: Introduction
895
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
895
01:26Peptic Ulcer Disease IV: Management
542
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
542
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
1.3K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.3K